Stoke Therapeutics (STOK) Capital Expenditures Growth (3y) (2021 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) Capital Expenditures Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 23.48% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 63.07% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -45.93% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | -40.95% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 29.63% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 60.74% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 27.08% |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 62.68% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 62.68% |
| Mar 31, 2026 | -13.48% |
| Dec 31, 2025 | -17.22% |
| Sep 30, 2025 | -59.79% |
| Jun 30, 2025 | -39.11% |
| Mar 31, 2025 | -43.46% |
| Dec 31, 2024 | -46.22% |
| Sep 30, 2024 | -27.74% |
| Jun 30, 2024 | -55.44% |
| Mar 31, 2024 | -61.11% |
| Dec 31, 2023 | 36.52% |
| Sep 30, 2023 | 12.50% |
| Jun 30, 2023 | 78.28% |
| Mar 31, 2023 | -3.69% |
| Dec 31, 2022 | -10.37% |
| Sep 30, 2022 | 51.57% |
| Jun 30, 2022 | 33.60% |
| Mar 31, 2022 | 61.95% |
| Dec 31, 2021 | 42.66% |
| Sep 30, 2021 | -19.12% |